NIKKEI 225
28,708.58 -546.97 (-1.87%) HANG SENG
26,017.53 -118.49 (-0.45%) GOLD FUTURES
1,782.80 -2.10 (-0.12%) DOW
35,488.11 -121.23 (-0.34%) BTC-GBP
45,912.34 -2,621.16 (-5.40%) CMC Crypto 200
1,501.20 -33.45 (-2.18%)
MEDICLIN Aktiengesellschaft (0NDG.L)
| Previous close | 5.25 |
| Open | 5.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.25 - 5.25 |
| 52-week range | 5.25 - 5.25 |
| Volume | 5,000 |
| Avg. volume | N/A |
| Market cap | 243.576M |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.33 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
MediClin AG: The demand for non-corona-induced medical and therapeutic measures has been increasing since mid-2021
DGAP-News: MediClin AG / Key word(s): Half Year Results30.07.2021 / 13:10 The issuer is solely responsible for the content of this announcement.The demand for non-corona-induced medical and therapeutic measures has been increasing since mid-2021In the first months of 2021 - due to the 3rd wave of the corona pandemic - there was still a low number of referrals from acute clinics and a reluctance to make use of rehabilitation services. This led only to a hesitant increase in occupancy in the first
- EQS Group
MediClin AG: Dr. Joachim Ramming becomes the new CEO of MEDICLIN
DGAP-News: MediClin AG / Key word(s): Personnel11.06.2021 / 12:41 The issuer is solely responsible for the content of this announcement.Dr. Joachim Ramming becomes the new CEO of MEDICLINIn today's meeting, the Supervisory Board of MEDICLIN Aktiengesellschaft (MEDICLIN) has appointed Dr. Joachim Ramming as member of the Management Board of MEDICLIN and as Chairman of the Board. The PhD economist and health economist will succeed Volker Hippler on August 1, 2021, who is resigning his mandate as C
- EQS Group
MEDICLIN focuses on patient safety and innovative concepts in rehabilitation
DGAP-News: MediClin AG / Key word(s): AGM/EGM28.05.2021 / 09:26 The issuer is solely responsible for the content of this announcement.MEDICLIN focuses on patient safety and innovative concepts in rehabilitationAt the Annual General Meeting of MEDICLIN Aktiengesellschaft (MEDICLIN) held on May 26, 2021, Chairman of the Management Board Volker Hippler gave a mixed picture of the situation. After the focus of the health policy and legislative measures aimed at preventing an overload of the health system, MEDICLIN reacted quickly and professionally to the new requirements. "We have fulfilled our responsibility as a health care provider in dealing with the pandemic, even if this left its mark on our earning power in the 2020 financial year", said Volker Hippler, explaining the business development.Tino Fritz, Chief Financial Officer of MEDICLIN, commented on the current situation as follows in response to a shareholder question: "Of course we are working on getting the occupancy up again, but the sales and earnings development for the year as a whole will depend on the development of the pandemic and the level of protective shielding benefits. These will be much lower for the year 2021."Overall, the protective shield benefits decided by politicians and the payments from the cost providers, as in the 2020 financial year, only compensate for a small part of the capacity losses and the higher costs.Patient safety comes firstIn his speech, the CEO emphasized that the focus is on the health and thus the safety of patients and employees. The hygiene concepts work well, as do the treatment and therapy concepts under special corona-related requirements. The feedback on patient satisfaction confirms this for the Group.Competence in post-COVID and long-COVID treatmentsHe particularly highlighted the interdisciplinary expertise that MEDICLIN has in the treatment of post-COVID and long-COVID patients. Pneumology experts work closely with experts in neurology, cardiology, psychiatry and psychosomatics. MEDICLIN has so far treated successfully more than 1,250 corona patients, and demand has risen sharply.Innovative concepts in rehabilitationDr. York Dhein, Member of the Management Board of MEDICLIN and responsible for this business segment, explained the future requirements of a performance based rehabilitation. "It will be a particular challenge to adapt rehabilitation to the changing demographic and social requirements with innovative performance-based concepts," he said and added: "That we can quickly build up and implement knowledge in our company MEDICLIN has shown in the treatment of post- and long-COVID patients."Information on the Annual General MeetingAt the Annual General Meeting of MEDICLIN Aktiengesellschaft 91.81% of the share capital was represented.With a large majority of 96.81%, the Annual General Meeting passed a new remuneration system for the Management Board.The actions of the Board of Management and the Supervisory Board were approved for 2020 with majorities of 98.57% and 98.41%, respectively.Because of the pandemic, the event again took place virtually on the Internet to protect the health of all those involved.About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)MEDICLIN includes 35 clinics, seven care facilities and ten medical care centers. The Group has around 8,350 beds / care places and employs around 10,300 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.MEDICLIN ─ a Company of the Asklepios-Group.28.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: alexandra.muehr@mediclin.de Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1201934 End of News DGAP News Service
